Novel directions in inflammation as a therapeutic target in atherosclerosis

Current Opinion in Lipidology

Volumn 26, Issue 6, 2015, Pages 580-585

  Verweij, Simone L ^a   Van Der Valk, Fleur M ^a   Stroes, Erik S G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

anti inflammatory strategies; arterial wall inflammation; atherosclerosis

Indexed keywords

ANTIINFLAMMATORY AGENT; INTERLEUKIN 1; INTERLEUKIN 6;

ATHEROGENESIS; ATHEROSCLEROSIS; BONE MARROW; CARDIAC PATIENT; CARDIOVASCULAR INFLAMMATION; CELL PROLIFERATION; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY ARTERY ATHEROSCLEROSIS; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPLEEN; SYSTEMIC THERAPY; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MOLECULAR TARGETED THERAPY;

EID: 84957436143     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000233     Document Type: Review

References (63)

1. Linsel-Nitschke P, Götz A, Erdmann J, et al. Lifelong reduction of LDLcholesterol related to a common varriant in the LDL-receptor gene decreases the risk of coronary artery disease: a Mendelian randomisation study. PLoS One 2008; 3:e2986.
2. Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein: an analysis. N Engl J Med 2008; 359:2195-2207.
3. Roth Ga, Forouzanfar MH, Moran AE, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med 2015; 372:1333-1341.
4. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473:317-325.
5. Golia E, Limongelli G, Natale F, et al. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Curr Atheroscler Rep 2014; 16:435.
6. Bäck M, Hansson GK. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol 2015; 12:199-211.
7. Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014; 35:1782-1791.
8. Ridker PM, Thuren T, Zalewski A, et al. Interleukin-1B inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). JT Am Heart J. 2011; 162:597-605.
9. Everett BM, Pradhan A D, Solomon D H, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013; 166:199-207.
10. Van der Valk FM, van Wijk DF, Stroes ESG. Novel anti-inflammatory strategies in atherosclerosis. Curr Opin Lipidol 2012; 23:532-539.
11. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108:1362-1370.
12. Sarwar N, Butterworth AS. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012; 379:1205-1213.
13. Swerdlow DI, Holmes MV, Kuchenbaecker KB, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012; 379:1214-1224.
14. Protogeroua D. Zampeli E, Fragiadaki K, et al. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 2011; 219:734-736.
15. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464:1357-1361.
16. Rajamaki K, Lappalainen J, Öörni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010; 5:1-9.
17. Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1b inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen a phase IIb randomized, placebo-controlled trial. Circulation 2012; 126:2739-2748.
18. Interleukin 1 Genetics Consortium. cardiometabolic effects of genetic upregulation of the IL1 receptor antanogist mendelian randomisatin analysis. Lancet Diabetes Endocrinol 2015; 3:243-254.
19. Ikonomidis I, Tzortzis S, Lekakis J, et al. Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart 2009; 95:1502-1507.
20. Abbate A, Kontos MC, Grizzard JD, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study). Am J Cardiol 2010; 105:1371-1377; e1.
21. Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the virginia commonwealth university-anakinra remodeling trial (2) (vcu-art2) pilot study]. Am J Cardiol 2013; 111:1394-1400.
22. Morton AC, Rothman AMK, Greenwood JP, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J 2015; 36:377-384.
23. Abbbate A, Kontos MC, Abouzaki NA. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiology 2015; 115:288-292.
24. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation 2010; 121:2437-2445.
25. Ammirati E, Moroni F, Magnoni M, et al. The role of T and B cells in human atherosclerosis and atherothrombosis. Clin Exp Immunol 2015; 179:173-187.
26. Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009; 325:612-616.
27. Robbins CS, Chudnovskiy A, Rauch PJ, et al. Extramedullary hematopoiesis generates Ly-6C high monocytes that infiltrate atherosclerotic lesions. Circulation 2012; 125:364-374.
28. Courties G, Herisson F, Sager H, et al. Ischemic stroke activates hematopoietic bone marrow stem cells. Circ Res 2015; 116:407-417.
29. Dutta P, Courties G, Wei Y, et al. Myocardial infarction accelerates atherosclerosis. Nature 2012; 487:325-329.
30. Emami H, Singh P, MacNabb M, et al. Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. JACC Cardiovasc Imaging 2015; 8:121-130.
31. Kim EJ, Kim S, Kang DO, et al. Metabolic activity of the spleen and bone marrow in patients with acute myocardial infarction evaluated by 18F-fluorodeoxyglucose positron emission tomograpic imaging. Circ Cardiovasc Imaging 2014; 7:454-460.
32. Katayama Y, Battista M, Kao WM, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 2006; 124:407-421.
33. Pasquié J, Ph D, Scavée C, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
34. Roolvink V, Rasoul S, Ottervanger JP, et al. Rationale and design of a doubleblind, multicenter, randomized, placebo-controlled clinical trial of early administration of intravenous b-blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention: EAR. Am Heart J 2014; 168:661-666.
35. Kleinnijenhuis J, Quintin J, Preijers F, et al. Long-lasting effects of bcg vaccination on both heterologous th1/th17 responses and innate trained immunity. J Innate Immun 2014; 6:152-158.
36. Kleinnijenhuis J, Quintin J, Preijers F, et al. From the cover: Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci 2012; 109:17537-17542.
37. Quintin J, Saeed S, Martens JHA, et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 2012; 12:223-232.
38. Bekkering S, Quintin J, Joosten LAB, et al. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. Arterioscler Thromb Vasc Biol 2014; 34:1731-1738.
39. Saeed S, Quintin J, Kerstens HHD, et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 2014; 345.
40. Nebbioso A, Carafa V, Benedetti R, et al. Trials with 'epigenetic' drugs: an update. Mol Oncol 2012; 6:657-682.
41. Kircher MF, Grimm J, Swirski FK, et al. Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation 2008; 117: 388-395.
42. Swirski FK, Pittet MJ, Kircher MF, et al. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A 2006; 103:10340-10345.
43. Leuschner F, Dutta P, Gorbatov R, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 2011; 29:1005-1010.
44. Okamoto M, Fuchigami M, Suzuki T, et al. A novel C-C chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models. Biol Pharm Bull 2012; 35:2069-2074.
45. Van der Valk FM, Kroon J, Potters WV, et al. In vivo imaging of enhanced leukocyte accumulation in atherosclerotic lesions in humans. J Am Coll Cardiol 2014; 64:1019-1029.
46. Rudd JHF, Myers KS, Bansilal S, et al. 18fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible. Implications for atherosclerosis therapy trials. J Am Coll Cardiol 2007; 50:892-896.
47. Menezes L, Kotze C, Agu O, et al. Investigating vulnerable atheroma using combined F-18-FDG PET/CT angiography of carotid plaque with immunohistochemical validation. J Nucl Med 2011; 52:1698-1704.
48. Koenen RR, Weber C. Chemokines: established and novel targets in atherosclerosis. EMBO Mol Med 2011; 3:713-725.
49. Gilbert J, Lekstrom-Himes J, Donaldson D, et al. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol 2011; 107:906-911.
50. Dutta P, Sager HB, Stengel KR, et al. Myocardial infarction activates CCR2+ hematopoietic stem and progenitor cells. Cell Stem Cell 2015; 16:477-487.
51. Robbins CS, Hilgendorf I, Weber GF, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med 2013; 19:1166-1172.
52. Schrijvers DM, De Meyer GRY, Kockx MM, et al. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25:1256-1261.
53. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: The importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005; 25:2255-2264.
54. Thorp E, Subramanian M, Tabas I. The role of macrophages and dendritic cells in the clearance of apoptotic cells in advanced atherosclerosis. Eur J Immunol 2011; 41:2515-2518.
55. Thorp E, Vaisar T, Subramanian M, et al. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase Cd, and p38 mitogen-activated protein kinase (MAPK). J Biol Chem 2011; 286:33335-33344.
56. Tabas I, Garcia-Cardena G, Owens GK. The cell biology of disease: recent insights into the cellular biology of atherosclerosis. J Cell Biol 2015; 209:13-22.
57. Maik Drechsler, de Jong R, Rossaint J. Annexin a1 counteracts chemokineinduced aterial myeloid cell recruitment. Cir Res 2015; 827-835.
58. Fredman G, Kamaly N, Spolitu S, et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med 2015; 7:.
59. Schiener M, Hossann M, Viola JR. Nanomedicine-based strategies for treatment of atherosclerosis. Trends Mol Med 2014; 20:271-281.
60. Zimmermann TS, Lee ACH, Akinc A, et al. RNAi-mediated gene silencing in nonhuman primates. Nature 2006; 441:111-114.
61. Lobatto ME, Fayad ZA, Silvera S, et al. Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm 2010; 7:2020-2029.
62. Der Valk FM Van. van Wijk DF, Lobatto ME, et al. Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. Nanomed Nanotechnol 2015; 11:1039-1046.
63. Lobatto ME, Fuster V, Fayad ZA, et al. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov 2011; 10:835-852.